Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study Article Swipe
Eugene R. Bleecker
,
Michael S. Blaiss
,
Juby A. Jacob‐Nara
,
Lynn Huynh
,
Mei Sheng Duh
,
Tracy Guo
,
Mingchen Ye
,
Richard H. Stanford
,
Zhixiao Wang
,
Xavier Soler
,
Arpita Nag
,
Radhika Nair
,
Kinga Borsos
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.jaci.2024.07.029
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.jaci.2024.07.029
The US ADVANTAGE real-world study demonstrated a significant reduction in severe asthma exacerbations and SCS prescriptions for patients prescribed dupilumab compared with patients prescribed omalizumab during 12 months of follow-up.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.jaci.2024.07.029
- OA Status
- hybrid
- Cited By
- 10
- References
- 25
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4401836456
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4401836456Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.jaci.2024.07.029Digital Object Identifier
- Title
-
Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE studyWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-08-24Full publication date if available
- Authors
-
Eugene R. Bleecker, Michael S. Blaiss, Juby A. Jacob‐Nara, Lynn Huynh, Mei Sheng Duh, Tracy Guo, Mingchen Ye, Richard H. Stanford, Zhixiao Wang, Xavier Soler, Arpita Nag, Radhika Nair, Kinga BorsosList of authors in order
- Landing page
-
https://doi.org/10.1016/j.jaci.2024.07.029Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1016/j.jaci.2024.07.029Direct OA link when available
- Concepts
-
Dupilumab, Omalizumab, Asthma, Medicine, Medical prescription, Corticosteroid, Asthma exacerbations, Dermatology, Immunology, Intensive care medicine, Immunoglobulin E, Antibody, Pharmacology, Internal medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
10Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 8, 2024: 2Per-year citation counts (last 5 years)
- References (count)
-
25Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4401836456 |
|---|---|
| doi | https://doi.org/10.1016/j.jaci.2024.07.029 |
| ids.doi | https://doi.org/10.1016/j.jaci.2024.07.029 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/39186985 |
| ids.openalex | https://openalex.org/W4401836456 |
| fwci | 7.56315301 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000188 |
| mesh[1].descriptor_ui | D001249 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | drug therapy |
| mesh[1].descriptor_name | Asthma |
| mesh[2].qualifier_ui | Q000627 |
| mesh[2].descriptor_ui | D000069444 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | therapeutic use |
| mesh[2].descriptor_name | Omalizumab |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D008297 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Male |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D005260 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Female |
| mesh[5].qualifier_ui | Q000627 |
| mesh[5].descriptor_ui | D061067 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | therapeutic use |
| mesh[5].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D000328 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Adult |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D008875 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Middle Aged |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D014481 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | United States |
| mesh[9].qualifier_ui | Q000627 |
| mesh[9].descriptor_ui | D018927 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | therapeutic use |
| mesh[9].descriptor_name | Anti-Asthmatic Agents |
| mesh[10].qualifier_ui | Q000627 |
| mesh[10].descriptor_ui | D000305 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | therapeutic use |
| mesh[10].descriptor_name | Adrenal Cortex Hormones |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D012189 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Retrospective Studies |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000293 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Adolescent |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D016896 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Treatment Outcome |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D000368 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Aged |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D055815 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Young Adult |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D057186 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Comparative Effectiveness Research |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D018450 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Disease Progression |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D006801 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Humans |
| mesh[19].qualifier_ui | Q000188 |
| mesh[19].descriptor_ui | D001249 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | drug therapy |
| mesh[19].descriptor_name | Asthma |
| mesh[20].qualifier_ui | Q000627 |
| mesh[20].descriptor_ui | D000069444 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | therapeutic use |
| mesh[20].descriptor_name | Omalizumab |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D008297 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Male |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D005260 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Female |
| mesh[23].qualifier_ui | Q000627 |
| mesh[23].descriptor_ui | D061067 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | therapeutic use |
| mesh[23].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D000328 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Adult |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D008875 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Middle Aged |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D014481 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | United States |
| mesh[27].qualifier_ui | Q000627 |
| mesh[27].descriptor_ui | D018927 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | therapeutic use |
| mesh[27].descriptor_name | Anti-Asthmatic Agents |
| mesh[28].qualifier_ui | Q000627 |
| mesh[28].descriptor_ui | D000305 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | therapeutic use |
| mesh[28].descriptor_name | Adrenal Cortex Hormones |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D012189 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Retrospective Studies |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D000293 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Adolescent |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D016896 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Treatment Outcome |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D000368 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Aged |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D055815 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Young Adult |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D057186 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Comparative Effectiveness Research |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D018450 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | Disease Progression |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D006801 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Humans |
| mesh[37].qualifier_ui | Q000188 |
| mesh[37].descriptor_ui | D001249 |
| mesh[37].is_major_topic | True |
| mesh[37].qualifier_name | drug therapy |
| mesh[37].descriptor_name | Asthma |
| mesh[38].qualifier_ui | Q000627 |
| mesh[38].descriptor_ui | D000069444 |
| mesh[38].is_major_topic | True |
| mesh[38].qualifier_name | therapeutic use |
| mesh[38].descriptor_name | Omalizumab |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D008297 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Male |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D005260 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Female |
| mesh[41].qualifier_ui | Q000627 |
| mesh[41].descriptor_ui | D061067 |
| mesh[41].is_major_topic | True |
| mesh[41].qualifier_name | therapeutic use |
| mesh[41].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[42].qualifier_ui | |
| mesh[42].descriptor_ui | D000328 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | |
| mesh[42].descriptor_name | Adult |
| mesh[43].qualifier_ui | |
| mesh[43].descriptor_ui | D008875 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | |
| mesh[43].descriptor_name | Middle Aged |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D014481 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | United States |
| mesh[45].qualifier_ui | Q000627 |
| mesh[45].descriptor_ui | D018927 |
| mesh[45].is_major_topic | True |
| mesh[45].qualifier_name | therapeutic use |
| mesh[45].descriptor_name | Anti-Asthmatic Agents |
| mesh[46].qualifier_ui | Q000627 |
| mesh[46].descriptor_ui | D000305 |
| mesh[46].is_major_topic | True |
| mesh[46].qualifier_name | therapeutic use |
| mesh[46].descriptor_name | Adrenal Cortex Hormones |
| mesh[47].qualifier_ui | |
| mesh[47].descriptor_ui | D012189 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | |
| mesh[47].descriptor_name | Retrospective Studies |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D000293 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | Adolescent |
| mesh[49].qualifier_ui | |
| mesh[49].descriptor_ui | D016896 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | |
| mesh[49].descriptor_name | Treatment Outcome |
| type | article |
| title | Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study |
| biblio.issue | 6 |
| biblio.volume | 154 |
| biblio.last_page | 1510 |
| biblio.first_page | 1500 |
| topics[0].id | https://openalex.org/T10051 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2737 |
| topics[0].subfield.display_name | Physiology |
| topics[0].display_name | Asthma and respiratory diseases |
| topics[1].id | https://openalex.org/T12538 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9883000254631042 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2746 |
| topics[1].subfield.display_name | Surgery |
| topics[1].display_name | Eosinophilic Esophagitis |
| topics[2].id | https://openalex.org/T12528 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.986299991607666 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | IL-33, ST2, and ILC Pathways |
| funders[0].id | https://openalex.org/F4320311600 |
| funders[0].ror | https://ror.org/02f51rf24 |
| funders[0].display_name | Regeneron Pharmaceuticals |
| funders[1].id | https://openalex.org/F4320333587 |
| funders[1].ror | |
| funders[1].display_name | Sanofi Genzyme |
| is_xpac | False |
| apc_list.value | 4000 |
| apc_list.currency | USD |
| apc_list.value_usd | 4000 |
| apc_paid.value | 4000 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 4000 |
| concepts[0].id | https://openalex.org/C2779824493 |
| concepts[0].level | 3 |
| concepts[0].score | 0.9457312226295471 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q5315925 |
| concepts[0].display_name | Dupilumab |
| concepts[1].id | https://openalex.org/C2778564945 |
| concepts[1].level | 4 |
| concepts[1].score | 0.929415225982666 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q415392 |
| concepts[1].display_name | Omalizumab |
| concepts[2].id | https://openalex.org/C2776042228 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7199790477752686 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q35869 |
| concepts[2].display_name | Asthma |
| concepts[3].id | https://openalex.org/C71924100 |
| concepts[3].level | 0 |
| concepts[3].score | 0.6354999542236328 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[3].display_name | Medicine |
| concepts[4].id | https://openalex.org/C2426938 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5981193780899048 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q3355478 |
| concepts[4].display_name | Medical prescription |
| concepts[5].id | https://openalex.org/C2776804153 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5605072975158691 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q210420 |
| concepts[5].display_name | Corticosteroid |
| concepts[6].id | https://openalex.org/C2909082789 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5586545467376709 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q35869 |
| concepts[6].display_name | Asthma exacerbations |
| concepts[7].id | https://openalex.org/C16005928 |
| concepts[7].level | 1 |
| concepts[7].score | 0.39083364605903625 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q171171 |
| concepts[7].display_name | Dermatology |
| concepts[8].id | https://openalex.org/C203014093 |
| concepts[8].level | 1 |
| concepts[8].score | 0.3665379285812378 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[8].display_name | Immunology |
| concepts[9].id | https://openalex.org/C177713679 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3234560787677765 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q679690 |
| concepts[9].display_name | Intensive care medicine |
| concepts[10].id | https://openalex.org/C141105273 |
| concepts[10].level | 3 |
| concepts[10].score | 0.27578333020210266 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q79455 |
| concepts[10].display_name | Immunoglobulin E |
| concepts[11].id | https://openalex.org/C159654299 |
| concepts[11].level | 2 |
| concepts[11].score | 0.1719675064086914 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[11].display_name | Antibody |
| concepts[12].id | https://openalex.org/C98274493 |
| concepts[12].level | 1 |
| concepts[12].score | 0.14741510152816772 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[12].display_name | Pharmacology |
| concepts[13].id | https://openalex.org/C126322002 |
| concepts[13].level | 1 |
| concepts[13].score | 0.13718271255493164 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[13].display_name | Internal medicine |
| keywords[0].id | https://openalex.org/keywords/dupilumab |
| keywords[0].score | 0.9457312226295471 |
| keywords[0].display_name | Dupilumab |
| keywords[1].id | https://openalex.org/keywords/omalizumab |
| keywords[1].score | 0.929415225982666 |
| keywords[1].display_name | Omalizumab |
| keywords[2].id | https://openalex.org/keywords/asthma |
| keywords[2].score | 0.7199790477752686 |
| keywords[2].display_name | Asthma |
| keywords[3].id | https://openalex.org/keywords/medicine |
| keywords[3].score | 0.6354999542236328 |
| keywords[3].display_name | Medicine |
| keywords[4].id | https://openalex.org/keywords/medical-prescription |
| keywords[4].score | 0.5981193780899048 |
| keywords[4].display_name | Medical prescription |
| keywords[5].id | https://openalex.org/keywords/corticosteroid |
| keywords[5].score | 0.5605072975158691 |
| keywords[5].display_name | Corticosteroid |
| keywords[6].id | https://openalex.org/keywords/asthma-exacerbations |
| keywords[6].score | 0.5586545467376709 |
| keywords[6].display_name | Asthma exacerbations |
| keywords[7].id | https://openalex.org/keywords/dermatology |
| keywords[7].score | 0.39083364605903625 |
| keywords[7].display_name | Dermatology |
| keywords[8].id | https://openalex.org/keywords/immunology |
| keywords[8].score | 0.3665379285812378 |
| keywords[8].display_name | Immunology |
| keywords[9].id | https://openalex.org/keywords/intensive-care-medicine |
| keywords[9].score | 0.3234560787677765 |
| keywords[9].display_name | Intensive care medicine |
| keywords[10].id | https://openalex.org/keywords/immunoglobulin-e |
| keywords[10].score | 0.27578333020210266 |
| keywords[10].display_name | Immunoglobulin E |
| keywords[11].id | https://openalex.org/keywords/antibody |
| keywords[11].score | 0.1719675064086914 |
| keywords[11].display_name | Antibody |
| keywords[12].id | https://openalex.org/keywords/pharmacology |
| keywords[12].score | 0.14741510152816772 |
| keywords[12].display_name | Pharmacology |
| keywords[13].id | https://openalex.org/keywords/internal-medicine |
| keywords[13].score | 0.13718271255493164 |
| keywords[13].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.1016/j.jaci.2024.07.029 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S108525051 |
| locations[0].source.issn | 0091-6749, 1085-8725, 1097-6825 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0091-6749 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Journal of Allergy and Clinical Immunology |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_lineage_names | Elsevier BV |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of Allergy and Clinical Immunology |
| locations[0].landing_page_url | https://doi.org/10.1016/j.jaci.2024.07.029 |
| locations[1].id | pmid:39186985 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | The Journal of allergy and clinical immunology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/39186985 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5048656238 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-4767-3494 |
| authorships[0].author.display_name | Eugene R. Bleecker |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210125099 |
| authorships[0].affiliations[0].raw_affiliation_string | Mayo Clinic, Scottsdale, Ariz |
| authorships[0].institutions[0].id | https://openalex.org/I4210125099 |
| authorships[0].institutions[0].ror | https://ror.org/03jp40720 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I1330342723, https://openalex.org/I4210125099 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Mayo Clinic in Arizona |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Eugene Bleecker |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Mayo Clinic, Scottsdale, Ariz |
| authorships[1].author.id | https://openalex.org/A5078830607 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-0733-9408 |
| authorships[1].author.display_name | Michael S. Blaiss |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I25041050 |
| authorships[1].affiliations[0].raw_affiliation_string | Medical College of Georgia at Augusta University, Augusta, Ga |
| authorships[1].institutions[0].id | https://openalex.org/I25041050 |
| authorships[1].institutions[0].ror | https://ror.org/012mef835 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I25041050 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Augusta University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Michael Blaiss |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Medical College of Georgia at Augusta University, Augusta, Ga |
| authorships[2].author.id | https://openalex.org/A5037227971 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-5372-8762 |
| authorships[2].author.display_name | Juby A. Jacob‐Nara |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210111804 |
| authorships[2].affiliations[0].raw_affiliation_string | Sanofi, Bridgewater, NJ |
| authorships[2].institutions[0].id | https://openalex.org/I4210111804 |
| authorships[2].institutions[0].ror | https://ror.org/027vj4x92 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210111804 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Sanofi (United States) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Juby Jacob-Nara |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Sanofi, Bridgewater, NJ |
| authorships[3].author.id | https://openalex.org/A5026542617 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-3110-6775 |
| authorships[3].author.display_name | Lynn Huynh |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I79463011 |
| authorships[3].affiliations[0].raw_affiliation_string | Analysis Group, Inc, Boston, Mass |
| authorships[3].institutions[0].id | https://openalex.org/I79463011 |
| authorships[3].institutions[0].ror | https://ror.org/044jp1563 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I79463011 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Analysis Group (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Lynn Huynh |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Analysis Group, Inc, Boston, Mass |
| authorships[4].author.id | https://openalex.org/A5063896009 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-5035-6687 |
| authorships[4].author.display_name | Mei Sheng Duh |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I79463011 |
| authorships[4].affiliations[0].raw_affiliation_string | Analysis Group, Inc, Boston, Mass |
| authorships[4].institutions[0].id | https://openalex.org/I79463011 |
| authorships[4].institutions[0].ror | https://ror.org/044jp1563 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I79463011 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Analysis Group (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Mei Sheng Duh |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Analysis Group, Inc, Boston, Mass |
| authorships[5].author.id | https://openalex.org/A5014207358 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Tracy Guo |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I79463011 |
| authorships[5].affiliations[0].raw_affiliation_string | Analysis Group, Inc, Boston, Mass |
| authorships[5].institutions[0].id | https://openalex.org/I79463011 |
| authorships[5].institutions[0].ror | https://ror.org/044jp1563 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I79463011 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Analysis Group (United States) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Tracy Guo |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Analysis Group, Inc, Boston, Mass |
| authorships[6].author.id | https://openalex.org/A5023351695 |
| authorships[6].author.orcid | https://orcid.org/0009-0000-5915-5523 |
| authorships[6].author.display_name | Mingchen Ye |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I79463011 |
| authorships[6].affiliations[0].raw_affiliation_string | Analysis Group, Inc, Boston, Mass |
| authorships[6].institutions[0].id | https://openalex.org/I79463011 |
| authorships[6].institutions[0].ror | https://ror.org/044jp1563 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I79463011 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Analysis Group (United States) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Mingchen Ye |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Analysis Group, Inc, Boston, Mass |
| authorships[7].author.id | https://openalex.org/A5053240270 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-5795-1147 |
| authorships[7].author.display_name | Richard H. Stanford |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210119849 |
| authorships[7].affiliations[0].raw_affiliation_string | AESARA, Inc, Chapel Hill, NC |
| authorships[7].institutions[0].id | https://openalex.org/I4210119849 |
| authorships[7].institutions[0].ror | https://ror.org/02krr1j33 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210119849 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Telesage (United States) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Richard H. Stanford |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | AESARA, Inc, Chapel Hill, NC |
| authorships[8].author.id | https://openalex.org/A5101687093 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-1928-3103 |
| authorships[8].author.display_name | Zhixiao Wang |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I186523950 |
| authorships[8].affiliations[0].raw_affiliation_string | Regeneron Pharmaceuticals, Inc, Tarrytown, NY |
| authorships[8].institutions[0].id | https://openalex.org/I186523950 |
| authorships[8].institutions[0].ror | https://ror.org/02f51rf24 |
| authorships[8].institutions[0].type | company |
| authorships[8].institutions[0].lineage | https://openalex.org/I186523950 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Regeneron (United States) |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Zhixiao Wang |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Regeneron Pharmaceuticals, Inc, Tarrytown, NY |
| authorships[9].author.id | https://openalex.org/A5113846151 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Xavier Soler |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I186523950 |
| authorships[9].affiliations[0].raw_affiliation_string | Regeneron Pharmaceuticals, Inc, Tarrytown, NY |
| authorships[9].institutions[0].id | https://openalex.org/I186523950 |
| authorships[9].institutions[0].ror | https://ror.org/02f51rf24 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I186523950 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Regeneron (United States) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Xavier Soler |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Regeneron Pharmaceuticals, Inc, Tarrytown, NY |
| authorships[10].author.id | https://openalex.org/A5087241362 |
| authorships[10].author.orcid | https://orcid.org/0000-0001-5195-3504 |
| authorships[10].author.display_name | Arpita Nag |
| authorships[10].countries | FR |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I3018075036 |
| authorships[10].affiliations[0].raw_affiliation_string | Sanofi, Cambridge, Mass |
| authorships[10].institutions[0].id | https://openalex.org/I3018075036 |
| authorships[10].institutions[0].ror | https://ror.org/02n6c9837 |
| authorships[10].institutions[0].type | company |
| authorships[10].institutions[0].lineage | https://openalex.org/I3018075036 |
| authorships[10].institutions[0].country_code | FR |
| authorships[10].institutions[0].display_name | Sanofi (France) |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Arpita Nag |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Sanofi, Cambridge, Mass |
| authorships[11].author.id | https://openalex.org/A5091740623 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-6585-3384 |
| authorships[11].author.display_name | Radhika Nair |
| authorships[11].countries | FR |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I3018075036 |
| authorships[11].affiliations[0].raw_affiliation_string | Sanofi, Cambridge, Mass |
| authorships[11].institutions[0].id | https://openalex.org/I3018075036 |
| authorships[11].institutions[0].ror | https://ror.org/02n6c9837 |
| authorships[11].institutions[0].type | company |
| authorships[11].institutions[0].lineage | https://openalex.org/I3018075036 |
| authorships[11].institutions[0].country_code | FR |
| authorships[11].institutions[0].display_name | Sanofi (France) |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Radhika Nair |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Sanofi, Cambridge, Mass |
| authorships[12].author.id | https://openalex.org/A5053984001 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Kinga Borsos |
| authorships[12].countries | FR |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I3018075036 |
| authorships[12].affiliations[0].raw_affiliation_string | Sanofi, Cambridge, Mass |
| authorships[12].institutions[0].id | https://openalex.org/I3018075036 |
| authorships[12].institutions[0].ror | https://ror.org/02n6c9837 |
| authorships[12].institutions[0].type | company |
| authorships[12].institutions[0].lineage | https://openalex.org/I3018075036 |
| authorships[12].institutions[0].country_code | FR |
| authorships[12].institutions[0].display_name | Sanofi (France) |
| authorships[12].author_position | last |
| authorships[12].raw_author_name | Kinga Borsos |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Sanofi, Cambridge, Mass |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1016/j.jaci.2024.07.029 |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10051 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2737 |
| primary_topic.subfield.display_name | Physiology |
| primary_topic.display_name | Asthma and respiratory diseases |
| related_works | https://openalex.org/W4282919436, https://openalex.org/W4237690111, https://openalex.org/W2140994897, https://openalex.org/W3033673073, https://openalex.org/W3005162812, https://openalex.org/W3213127005, https://openalex.org/W2983055706, https://openalex.org/W2554465708, https://openalex.org/W2326340126, https://openalex.org/W2607349441 |
| cited_by_count | 10 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 8 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 2 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1016/j.jaci.2024.07.029 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S108525051 |
| best_oa_location.source.issn | 0091-6749, 1085-8725, 1097-6825 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0091-6749 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Journal of Allergy and Clinical Immunology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_lineage_names | Elsevier BV |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of Allergy and Clinical Immunology |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.jaci.2024.07.029 |
| primary_location.id | doi:10.1016/j.jaci.2024.07.029 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S108525051 |
| primary_location.source.issn | 0091-6749, 1085-8725, 1097-6825 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0091-6749 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Journal of Allergy and Clinical Immunology |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_lineage_names | Elsevier BV |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of Allergy and Clinical Immunology |
| primary_location.landing_page_url | https://doi.org/10.1016/j.jaci.2024.07.029 |
| publication_date | 2024-08-24 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W2809988035, https://openalex.org/W2888190336, https://openalex.org/W2803941918, https://openalex.org/W1489784156, https://openalex.org/W2342693354, https://openalex.org/W2167829087, https://openalex.org/W2883343622, https://openalex.org/W4280544756, https://openalex.org/W6776577717, https://openalex.org/W3176692335, https://openalex.org/W4376321189, https://openalex.org/W2913129262, https://openalex.org/W3205211596, https://openalex.org/W2051462629, https://openalex.org/W6770863101, https://openalex.org/W2034044876, https://openalex.org/W4283120210, https://openalex.org/W4319075002, https://openalex.org/W4312052000, https://openalex.org/W2974441349, https://openalex.org/W1975994236, https://openalex.org/W2040113464, https://openalex.org/W1967862917, https://openalex.org/W2990547654, https://openalex.org/W3016825251 |
| referenced_works_count | 25 |
| abstract_inverted_index.a | 6 |
| abstract_inverted_index.12 | 26 |
| abstract_inverted_index.US | 1 |
| abstract_inverted_index.in | 9 |
| abstract_inverted_index.of | 28 |
| abstract_inverted_index.SCS | 14 |
| abstract_inverted_index.The | 0 |
| abstract_inverted_index.and | 13 |
| abstract_inverted_index.for | 16 |
| abstract_inverted_index.with | 21 |
| abstract_inverted_index.study | 4 |
| abstract_inverted_index.asthma | 11 |
| abstract_inverted_index.during | 25 |
| abstract_inverted_index.months | 27 |
| abstract_inverted_index.severe | 10 |
| abstract_inverted_index.compared | 20 |
| abstract_inverted_index.patients | 17, 22 |
| abstract_inverted_index.ADVANTAGE | 2 |
| abstract_inverted_index.dupilumab | 19 |
| abstract_inverted_index.reduction | 8 |
| abstract_inverted_index.follow-up. | 29 |
| abstract_inverted_index.omalizumab | 24 |
| abstract_inverted_index.prescribed | 18, 23 |
| abstract_inverted_index.real-world | 3 |
| abstract_inverted_index.significant | 7 |
| abstract_inverted_index.demonstrated | 5 |
| abstract_inverted_index.exacerbations | 12 |
| abstract_inverted_index.prescriptions | 15 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 94 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 13 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/2 |
| sustainable_development_goals[0].score | 0.6200000047683716 |
| sustainable_development_goals[0].display_name | Zero hunger |
| citation_normalized_percentile.value | 0.95159376 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |